Cellogen Therapeutics announced that it has received around $2 million in a round of funding on January 17, 2024. The transaction included participation from new investor, NATCO Pharma Limited.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
990 INR | +1.59% | -0.50% | +22.01% |
05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.01% | 2.09B | |
+29.27% | 682B | |
+30.64% | 586B | |
-3.11% | 364B | |
+17.87% | 327B | |
+4.07% | 285B | |
+16.58% | 240B | |
+9.97% | 209B | |
-8.59% | 203B | |
+7.46% | 165B |
- Stock Market
- Equities
- NATCOPHARM Stock
- News NATCO Pharma Limited
- Cellogen Therapeutics announced that it has received $2 million in funding from NATCO Pharma Limited